Roche Reports Phase 3 SKYSCRAPER-01 Results for Tiragolumab in PD-L1 High NSCLC

Roche today announced results from the Phase 3 SKYSCRAPER-01 trial evaluating tiragolumab plus atezolizumab versus atezolizumab plus placebo in patients with PD-L1 high non-small cell lung cancer. While the trial did not meet its co-primary endpoints of progression-free survival and overall survival in the overall population, exploratory analyses are ongoing to identify potential subgroups that may benefit.